Table 2

 Summary of reasons for discontinuation of treatment in phase II (6–18 months)

Combination groupSASP aloneMTX alone
MTX, methotrexate; SASP, sulfasalazine.
Intercurrent illness1
Side effects121014
Lack of effect242
Non-compliance/lost to follow-up2
Total171416